Is CJC-1295 Legal in Texas? How Women Can Access It Legally

The short legal answer for Texas women

CJC-1295 is not a federally scheduled controlled substance, but it is also not an FDA-approved drug. That in-between position means its legal status depends entirely on how you access it. In Texas, obtaining it through a valid prescription written by a licensed physician or nurse practitioner, filled at a state-licensed compounding pharmacy that operates within federal standards, is the pathway that places you on the right side of both state and federal law. Buying it as a "research chemical" online, without a prescription, is the path that carries real legal and health risk.

Perimenopause, PCOS, thyroid dysfunction, and postpartum metabolic changes are among the reasons women start researching growth hormone secretagogues. Understanding the legal structure first protects you before you spend a dollar.

Federal law: where CJC-1295 actually stands

The FDA has not approved CJC-1295 as a finished drug

No pharmaceutical company has submitted a New Drug Application (NDA) for CJC-1295. The FDA's database of approved drug products contains no entry for it. That means any CJC-1295 you encounter is either compounded, sold as a "research chemical," or obtained through channels that fall outside conventional pharmacy regulation.

The 503A vs 503B compounding distinction matters to you personally

Under the Federal Food, Drug, and Cosmetic Act, two sections govern compounding pharmacies.

503A covers traditional compounding pharmacies that prepare medications for individual patients based on a valid prescription from a licensed practitioner. To compound a drug under 503A, the active pharmaceutical ingredient (API) generally must appear on an FDA-approved list or meet specific criteria. The FDA maintains a "bulk drug substances" list for 503A. CJC-1295 was nominated for this list but has not been placed on the Category 1 list of bulk substances that may be used in compounding. That ambiguity creates real risk for compounding pharmacies using it under 503A.

503B covers outsourcing facilities that compound drugs in larger volumes, often without a patient-specific prescription. The 503B bulk drug substances list is separate, and CJC-1295 does not appear on the FDA's 503B bulk drug substances list as an approved substance either.

Is it a controlled substance?

CJC-1295 is not scheduled under the DEA Controlled Substances Act schedules. It is not a controlled substance the way testosterone or benzodiazepines are. But "not a controlled substance" does not mean "legal to sell freely." The FDA can and does take enforcement action against entities that sell unapproved drug products, including peptides marketed for human use. In 2023 and 2024 the FDA issued warning letters to multiple compounding pharmacies and online sellers for marketing peptides including growth hormone secretagogues outside the permitted compounding framework.

The gray zone, described honestly

The honest summary: CJC-1295 occupies a space where personal possession for medical use under a valid prescription is not criminally prosecuted, but the regulatory pathway for pharmacies to legally compound and dispense it is narrow and contested. If a pharmacy is selling it to you without a prescription, or as a "research chemical" for "laboratory use only," that pharmacy is operating outside federal guidelines, and you bear the downstream risk.

Texas state law: what the Texas Medical Board and TSBP add

Texas does not add a separate CJC-1295 ban

Texas has no state statute that specifically names CJC-1295 or lists it as a prohibited substance. That is the good news. The Texas State Board of Pharmacy (TSBP) and the Texas Medical Board (TMB) defer to federal compounding law for the most part, layering Texas-specific requirements on top rather than replacing them.

Texas Medical Practice Act requirements for prescribers

Under the Texas Medical Practice Act, any Texas-licensed physician who prescribes CJC-1295 must have a valid prescriber-patient relationship, conduct an appropriate medical evaluation, and prescribe within the standard of care. Telehealth prescribing is explicitly permitted in Texas following permanent rules adopted after the COVID-era expansions, but it still requires a legitimate clinical encounter, a documented diagnosis or clinical indication, and prescriber oversight. An online questionnaire alone, with no video evaluation, does not meet the standard of care for peptide prescribing.

Texas State Board of Pharmacy and compounding rules

The TSBP licenses all pharmacies operating in Texas and requires compliance with state pharmacy law as well as USP standards (USP 795 for non-sterile and USP 797 for sterile compounding). Because CJC-1295 is administered as a subcutaneous injection, any compounded product must meet the sterile compounding requirements of USP 797. A TSBP-licensed pharmacy that compounds CJC-1295 for a Texas patient must also be working with an API from an FDA-registered source. Using a non-registered, unverified API source violates both state and federal rules and creates contamination risk that is clinically significant, particularly for women who are immunocompromised or postpartum.

How women can access CJC-1295 legally in Texas: the step-by-step path

Step 1: Find a Texas-licensed prescriber who specializes in women's metabolic health

Your starting point is a clinician licensed by the TMB or the Texas Board of Nursing (for nurse practitioners with prescriptive authority) who has training in peptide therapy, endocrinology, or women's metabolic health. The prescriber must document a clinical reason for prescribing. Common documented indications include adult growth hormone deficiency supported by lab testing, or off-label use for metabolic support in conditions such as PCOS with insulin resistance. "I want to lose weight" alone is unlikely to constitute a documented clinical indication under a standard-of-care framework.

Step 2: Undergo a real medical evaluation

A proper evaluation includes a clinical history, physical assessment (or thorough telehealth equivalent), and baseline labs. Relevant labs often ordered before growth hormone secretagogue therapy include:

• IGF-1 (insulin-like growth factor 1)
• Fasting glucose and insulin (HOMA-IR for PCOS screening)
• Thyroid panel (TSH, free T4, free T3)
• Comprehensive metabolic panel
• Lipid panel
• Sex hormones relevant to your life stage (estradiol, FSH, LH, testosterone, DHEA-S)

For perimenopausal women, IGF-1 naturally declines with estrogen loss. A prescriber who does not check baseline IGF-1 before starting a GHRH analog is not following a defensible standard of care.

Step 3: Prescription sent to a compliant compounding pharmacy

Your prescriber sends a patient-specific prescription to a 503A-licensed, TSBP-registered compounding pharmacy that uses USP 797-compliant sterile compounding practices. You should ask the pharmacy directly whether its CJC-1295 API comes from an FDA-registered supplier and whether the finished product undergoes third-party potency and sterility testing. A reputable pharmacy will provide a certificate of analysis (COA) on request.

Step 4: Ongoing monitoring

CJC-1295 is not a "set it and forget it" therapy. Responsible prescribers recheck IGF-1 at 8-12 weeks to ensure levels remain within a safe physiological range. Supraphysiological IGF-1 is associated with increased cancer risk in observational data, and this concern is especially relevant given that IGF-1 signaling has been implicated in breast cancer biology. That monitoring visit is not optional.

Sex-specific physiology: why this is different for women

The estrogen-GH axis

Estrogen modulates growth hormone secretion at the pituitary level. Premenopausal women naturally have higher pulsatile GH secretion than men of the same age, partly because estrogen amplifies GH pulse amplitude. A published pharmacokinetic analysis of CJC-1295 demonstrated dose-dependent increases in GH and IGF-1 across both sexes, but the trial enrolled primarily men and healthy young adults. Women were included but not analyzed as a separate subgroup in most published data. This is a direct example of the evidence gap described in rule W6: what we know about CJC-1295 pharmacokinetics in women is largely extrapolated, not directly studied.

Perimenopause and postmenopause

The perimenopausal decline in estrogen reduces GH pulse amplitude, contributing to changes in body composition, increased visceral adiposity, and muscle loss. This is one reason women in their 40s and early 50s sometimes seek growth hormone secretagogues. However, no randomized controlled trial has specifically studied CJC-1295 in perimenopausal or postmenopausal women. The FDA-approved growth hormone replacement literature is the closest reference point, and even that literature shows sex differences in GH sensitivity and IGF-1 response that are directly relevant.

Postmenopausal women on oral estrogen therapy have lower IGF-1 levels than women on transdermal estrogen, because oral estrogen undergoes hepatic first-pass metabolism that suppresses hepatic IGF-1 production. If you are postmenopausal and on oral hormone therapy, your prescriber needs to know this when interpreting baseline IGF-1, because a "low" IGF-1 on oral estrogen may not reflect true GH deficiency.

PCOS and insulin resistance

Women with PCOS frequently have elevated basal insulin and altered GH secretion patterns. Some research suggests GH pulse amplitude is blunted in women with hyperinsulinemic PCOS. The theoretical rationale for a GHRH analog in PCOS-related metabolic dysfunction exists, but no peer-reviewed trial has tested CJC-1295 specifically in women with PCOS. Given that PCOS affects an estimated 8-13% of women of reproductive age globally, the absence of targeted trial data is a meaningful gap.

The menstrual cycle

GH secretion varies across the menstrual cycle, peaking in the follicular phase when estrogen rises. Timing of IGF-1 lab draws relative to cycle phase matters for interpretation. A draw on day 2-3 (low estrogen, baseline) will read differently from a draw on day 12-14 (LH surge, estrogen peak). Ask your prescriber whether they account for cycle phase when ordering and interpreting IGF-1.

Pregnancy, lactation, and contraception: a required section for any woman of reproductive age

CJC-1295 is contraindicated in pregnancy. There are no adequate human safety data, and no animal reproduction studies have been published in peer-reviewed literature. Growth hormone axis manipulation during pregnancy carries theoretical risk of disrupting fetal IGF-1 signaling, which is essential for normal fetal growth and placental function. No responsible clinician should prescribe CJC-1295 to a pregnant woman.

If you are trying to conceive, stop CJC-1295 before attempting pregnancy. The half-life of the DAC (Drug Affinity Complex) formulation of CJC-1295 extends its duration of action to approximately 6-8 days per the original Teichman et al. (2006) pharmacokinetic study published in the Journal of Clinical Endocrinology & Metabolism. A washout period of at least 4 weeks before conception attempts is a conservative and appropriate recommendation given the absence of safety data.

Lactation: There are no human data on CJC-1295 transfer into breast milk. Given that growth hormone and IGF-1 are present in human milk physiologically and contribute to infant gut development, exogenously manipulating the maternal GH axis during lactation introduces theoretical risks that have not been studied. The conservative recommendation is to avoid CJC-1295 while breastfeeding.

Contraception: Any woman of reproductive age using CJC-1295 should use reliable contraception for the duration of treatment. This is not a requirement imposed by a regulatory body (because CJC-1295 lacks that regulatory framework), but it is the standard-of-care recommendation any responsible prescriber should document.

Who this is appropriate for, and who it is not

The following framework is based on the WomanRx clinical editorial board's review of available pharmacokinetic data, FDA compounding guidance, and standard-of-care principles for growth hormone secretagogue therapy in women. No published guideline from ACOG, The Menopause Society, or ASRM currently addresses CJC-1295 specifically.

Women for whom a conversation with a prescriber is reasonable

• Adult women with documented low IGF-1 on lab testing and symptoms consistent with GH deficiency (fatigue, increased visceral fat, muscle loss, poor sleep quality) who have not responded to lifestyle optimization
• Postmenopausal women on transdermal (not oral) hormone therapy with a genuine metabolic indication, after ruling out thyroid dysfunction and other reversible causes
• Women with PCOS who have a prescriber willing to monitor closely and acknowledge the absence of PCOS-specific trial data

Women for whom CJC-1295 is not appropriate at this time

• Pregnant women or those actively trying to conceive
• Breastfeeding women
• Women with active or personal history of hormone-sensitive cancers (breast, ovarian, endometrial) given the IGF-1 and cancer biology concern
• Women with uncontrolled diabetes or significant insulin resistance without specialist oversight, as GH secretagogues can raise fasting glucose
• Women with acromegaly or any condition of GH excess
• Women who cannot access a licensed Texas prescriber and a compliant compounding pharmacy and are considering online "research chemical" purchases as an alternative

A note on telehealth in Texas

Texas permanently expanded telehealth prescribing authority. You can legally receive a CJC-1295 prescription from a Texas-licensed telehealth provider without an in-person visit, provided the provider conducts a thorough clinical evaluation, reviews your labs, documents a clinical indication, and maintains an ongoing prescriber-patient relationship. A three-minute intake form with no video visit and no lab review does not meet that standard, and any prescription generated that way carries regulatory risk for the prescriber and safety risk for you.

The "research chemical" market: why it is a different legal category

Searching online for CJC-1295 will surface dozens of vendors selling it labeled "for research use only, not for human consumption." This language is a legal shield for the seller, not a protection for you. Purchasing and self-injecting a product sold under that label means:

• No physician oversight or monitoring
• No guarantee of sterility (subcutaneous injection of a non-sterile product can cause abscess, bacteremia, and sepsis)
• No verified API potency (independent analyses of research-chemical peptides have found doses ranging from 0% to 200%+ of labeled content)
• Potential violation of FDA regulations on unapproved new drug products
• No legal recourse if you are harmed

The FDA has specifically warned consumers about purchasing peptides from unregulated online sources. That guidance applies to Texas residents as it does to any other American.

Comparing legal access options in Texas

| Access path | Prescription required | Texas-licensed pharmacy | Sterility verified | Recommended | |---|---|---|---|---| | TMB-licensed prescriber plus TSBP-licensed 503A compounder | Yes | Yes | Yes (USP 797) | Yes | | Telehealth prescriber (TX-licensed) plus compliant compounder | Yes | Yes | Yes (USP 797) | Yes, with proper evaluation | | Online "research chemical" vendor | No | No | No | No | | Out-of-state 503B outsourcing facility (without TX-licensed Rx) | No | No | Varies | No |

What to ask your Texas prescriber before starting

1. Are you licensed by the Texas Medical Board or Texas Board of Nursing, and do you hold prescriptive authority?
2. Which compounding pharmacy do you use, and is it TSBP-registered and USP 797-compliant?
3. Can you provide the pharmacy's certificate of analysis for the CJC-1295 batch?
4. What baseline labs do you require before prescribing?
5. How will you monitor my IGF-1 levels during treatment, and what level would prompt you to reduce or stop the dose?
6. What is your policy if I become pregnant or decide to try to conceive while on therapy?

A prescriber who cannot answer questions 1 through 3 clearly is not operating within a defensible standard of care.